Blood changes and cancer therapy study
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study looks at why some people develop blood disorders after cancer treatment. It monitors changes in blood cells to better predict and prevent these problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have or had ovarian, peritoneal, or fallopian tube cancer and have finished or plan to finish at least 5 rounds of platinum chemotherapy.
- Or, you have any solid tumor and have taken a PARP inhibitor (like olaparib) for at least 4 months.
- Or, you have any solid tumor and have been diagnosed with a blood disorder, such as clonal hematopoiesis, unexplained low blood counts, or a treatment-related bone marrow cancer.
- Your life expectancy must be more than 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people with solid tumors who are about to start chemotherapy or radiation. It looks at how these treatments affect blood cells and may help doctors understand changes in blood health over time.
This Phase 2 study tests whether adding two medicines—APL-2 plus pembrolizumab or pembrolizumab plus bevacizumab—works better than bevacizumab alone for recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also focuses on people who have symptoms from cancer-related fluid (ascites or pleural effusion).
This study will collect medical information from people with advanced ovarian, peritoneal, or fallopian tube cancer. The goal is to learn more about these cancers and improve future treatments.
This trial tests a new type of immune therapy called CAR T-cells (SCT-001) for ovarian cancer that has returned or isn't responding to standard treatments. The cells are engineered to find and attack cancer cells that have a specific marker (TAG-72) on their surface.
This is a study that collects information and samples from people diagnosed with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. It helps doctors better understand these cancers by building a clinical and biological database, which may improve care planning in the future.
This study looks at how CAR-T therapy affects blood cell counts (cytopenia) in people with multiple myeloma or certain lymphomas/leukemias. You will provide biological samples to help researchers understand these effects.
Hear when a new Recurrent Fallopian Tube Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.